02/01/2014

"Single intrathecal administration of the transcription factor decoy AYX1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injury"

SAN FRANCISCO, CALIF., February 1, 2014 – Adynxx’s lead product candidate, AYX1, was featured in the February issue of PAIN, the Journal of the International Association for the Study of Pain.  ... Full Report →

Adynxx (A - dȳ - nix), located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots - preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes. Adynxx's unique approach is to transform pain management by approaching pain as a disease rather than a symptom.
Adynxx's lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at the time of surgery.  Adynxx has completed Phase 1 and Phase 2 clinicals trial of AYX1.  Additional compounds targeting a range of intractable neuropathic and inflammatory pain syndromes are in the pre-clinical stage.